君实生物获批AWT020临床试验

财中社
05 Feb

财中社2月5日电君实生物(688180/01877)发布公告,近日公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,AWT020注射用无菌粉末(项目代号“JS213”)的临床试验申请获得批准。该药品的临床试验将主要针对晚期恶性肿瘤患者,开展单药以及联合其他抗肿瘤治疗的研究。JS213是一种PD-1和白细胞介素-2双功能性抗体融合蛋白,具有显著的抑瘤作用和良好的安全性。公告中提到,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10